Browsing Category
Pharma Industry News
4730 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Eli Lilly’s Jaypirca outpaces Imbruvica in landmark CLL head‑to‑head trial
Eli Lilly’s Jaypirca beats Imbruvica in a head-to-head CLL trial. Explore why this breakthrough matters for BTK therapy and cancer care.
ChemLex raises $45m to launch self-driving drug discovery lab in Singapore
ChemLex raises USD 45M to launch an AI-powered self-driving lab in Singapore. Find out how it plans to reshape drug discovery timelines worldwide.
CARsgen showcases early clinical results for CT0596 allogeneic BCMA CAR-T cell therapy in multiple myeloma
CARsgen unveils early CT0596 CAR-T trial results at ASH 2025, showing deep responses and strong tolerability in multiple myeloma. See what’s next for the therapy.
AL-S Pharma’s AP-101 prolongs survival and delays ventilator use in ALS Phase 2 trial
AL-S Pharma’s AP-101 showed survival and biomarker gains in ALS Phase 2 study. Find out what this means as the firm prepares for Phase 3.
Viatris (Nasdaq: VTRS) exits Biocon Biologics with $815m deal as biosimilars reentry accelerates
Viatris unlocks $815M from Biocon Biologics exit and regains biosimilars access. Find out how this reshapes its 2026 global pharma strategy.
Is Vivacta Bio’s GT801 the next frontier in CAR-T therapy? Early human data reveal scalable, chemo-free promise
Vivacta Bio’s GT801 shows early promise as a repeat-dose in vivo CAR-T therapy for lymphoma. Find out how this could reshape immunotherapy delivery.
Is Johnson & Johnson’s CARVYKTI shifting the multiple myeloma treatment curve?
Johnson & Johnson’s CARVYKTI shows 80% 30-month remission in earlier-line multiple myeloma. See how CARTITUDE-4 could change the treatment landscape.
Coronavirus is still evolving: The essential guide to symptoms, treatment options, and protection
Explore this complete guide on coronavirus symptoms, treatment options, and prevention tips to stay protected every year.
Can Partner Therapeutics’ zenocutuzumab-zbco deliver a first-line breakthrough in NRG1+ lung cancer?
Zenocutuzumab-zbco by Partner Therapeutics shows durable first-line response in NRG1+ NSCLC. Find out what the new eNRGy trial data means for patients.
Two years in, is Lundbeck’s bexicaserin redefining how we treat drug-resistant seizures?
Lundbeck’s bexicaserin shows two-year seizure control in rare epilepsies. Explore how the durable data could redefine drug development in childhood DEEs.